Overview

  • Product nameAnti-PLA2G3 antibody
    See all PLA2G3 primary antibodies
  • Description
    Rabbit polyclonal to PLA2G3
  • Tested applicationsSuitable for: IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human PLA2G3 (internal sequence) conjugated to Keyhole Limpet Haemocyanin (KLH).

  • Positive control
    • Human colonic carcinoma tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab62197 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 2.5 µg/ml.

Target

  • FunctionPA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Shows an 11-fold preference for phosphatidylglycerol over phosphatidylcholine (PC). Preferential cleavage: 1-palmitoyl-2-linoleoyl-phosphatidylethanolamine (PE) > 1-palmitoyl-2-linoleoyl-PC > 1-palmitoyl-2-arachidonoyl-PC > 1-palmitoyl-2-arachidonoyl-PE. Plays a role in ciliogenesis.
  • Tissue specificityExpressed in kidney, heart, liver, and skeletal muscle. Also present in placenta and peripheral blood leukocytes. Not detected in brain, colon, thymus, spleen and small intestine. In lung, expressed in bronchial epithelial cells and alveolar macrophages, but scarcely detected in alveolar epithelium, arterial walls and interstitial fibroblasts (at protein level). In joints of osteoarthritis and rheumatoid arthritis, expressed in endothelial cells (at protein level). In normal heart, detected in some vessels. In myocardial tissues with acute infarction, expressed in vascular endothelial cells adjacent to cardiomyocytes and those in lesions with granulation. Expression in cardiomyocytes is scarce (at protein level). In uterus, breast and colon cancers, detected in tumor cells and neighboring microvascular endothelium, but not in normal glandular tissues (at protein level).
  • Sequence similaritiesBelongs to the phospholipase A2 family.
  • Post-translational
    modifications
    N-glycosylation does not affect the catalytic activity, but is required for proper secretion. A nonglycosylated form was observed in several cell types.
    In several cell types, the N- and C-termini are cleaved off.
  • Cellular localizationSecreted. Cell membrane. Cytoplasm > cytoskeleton > centrosome > centriole.
  • Information by UniProt
  • Database links
  • Alternative names
    • EC 3.1.1.4 antibody
    • GIII sPLA2 antibody
    • Group 3 secretory phospholipase A2 antibody
    • Group III secretory phospholipase A2 antibody
    • PA2G3_HUMAN antibody
    • Phosphatidylcholine 2 acylhydrolase GIII antibody
    • Phosphatidylcholine 2-acylhydrolase 3 antibody
    • phospholipase A2 group III antibody
    • PLA2G3 antibody
    • sPLA2-III antibody
    • SPLA2III antibody
    see all

Anti-PLA2G3 antibody images

  • Immunohistochemical analysis of paraffin embedded colonic carcinoma tissue, using ab62197 at 2.5µg/ml.

References for Anti-PLA2G3 antibody (ab62197)

ab62197 has not yet been referenced specifically in any publications.

Product Wall

Thank you for your response.
Currently, we can't offer customer made peptide synthesis. It is very likely that we currently we do not have specific antibodies which could target the central S domain of the PLA2g3 protein (149-291 of the human PLA2...

Read More

Thank you for your enquiry.
These two antibodies are from two different sources, the manufacturing and the characterization processes are different thus the tested applications are not the same as you can see of the product datasheets.
I can ...

Read More

Thank you for your inquiry.
The exact sequence used to generate this antibody is considered proprietary but I can release that it is taken from within the general range of aa 160-210 of the human protein according to NP_056530.2, so it is within a...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"